Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
KG 
KING PHARMACEUTICALS INC (KG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: KG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -7.73% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 278.50M USD | Price to earnings Ratio 934 | 1Y Target Price - |
Price to earnings Ratio 934 | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 11.00 - 42.80 | Updated Date 06/29/2025 |
52 Weeks Range 11.00 - 42.80 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.03 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE 934 | Forward PE - | Enterprise Value 269592162 | Price to Sales(TTM) 52.12 |
Enterprise Value 269592162 | Price to Sales(TTM) 52.12 | ||
Enterprise Value to Revenue 51.35 | Enterprise Value to EBITDA 1901.72 | Shares Outstanding 9939500 | Shares Floating - |
Shares Outstanding 9939500 | Shares Floating - | ||
Percent Insiders - | Percent Institutions 672.25 |
Upturn AI SWOT
KING PHARMACEUTICALS INC
Company Overview
History and Background
King Pharmaceuticals was founded in 1994 and headquartered in Bristol, Tennessee. It focused on developing, manufacturing, and marketing branded prescription pharmaceutical products. A significant milestone was its acquisition of Monarch Pharmaceuticals in 1998. The company was acquired by Pfizer in 2011.
Core Business Areas
- Pain Management: Developed and marketed opioid pain medications. Products included Avinza and Embeda.
- Cardiovascular: Included products related to heart health and blood pressure management.
- Hospital Products: Offered a range of products used in hospital settings.
Leadership and Structure
Before its acquisition, King Pharmaceuticals was led by a board of directors and a management team headed by a CEO. The organizational structure included departments for research and development, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Avinza: An extended-release morphine sulfate capsule used for the management of chronic pain. Market share data is not readily available due to subsequent generic entrants and the acquisition by Pfizer. Competitors included Purdue Pharma (OxyContin) and Endo Pharmaceuticals (Opana ER).
- Embeda: A morphine sulfate and naltrexone hydrochloride extended-release capsule. Like Avinza, market share data is difficult to obtain post-acquisition. Competitors included other opioid analgesics.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with a focus on research and development, manufacturing, and marketing of prescription drugs. Patent protection and regulatory approvals play critical roles.
Positioning
King Pharmaceuticals focused on specific therapeutic areas, including pain management and cardiovascular health. Its competitive advantages stemmed from its product portfolio and marketing capabilities. They developed a painkiller named Skelaxin as well.
Total Addressable Market (TAM)
The global pharmaceutical market is worth trillions of dollars. King Pharmaceuticals' TAM was related to its specific product lines. With the acquisition by Pfizer, the TAM is rolled into the parent company's valuation.
Upturn SWOT Analysis
Strengths
- Established product portfolio
- Strong marketing capabilities
- Experienced management team
- Focus on niche therapeutic areas
Weaknesses
- Reliance on opioid pain medications
- Exposure to patent expirations
- Dependence on regulatory approvals
- Competition from larger pharmaceutical companies
Opportunities
- Expansion into new therapeutic areas
- Acquisition of complementary businesses
- Development of novel drug delivery systems
- Partnerships with biotechnology companies
Threats
- Increasing generic competition
- Stricter regulatory scrutiny
- Product liability lawsuits
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- PFE
- JNJ
- MRK
- ABBV
Competitive Landscape
Before its acquisition, King Pharmaceuticals competed with larger pharmaceutical companies by focusing on niche therapeutic areas and developing strong marketing strategies. Its competitive advantage was primarily its ability to effectively market and distribute its products.
Major Acquisitions
Monarch Pharmaceuticals
- Year: 1998
- Acquisition Price (USD millions): 660
- Strategic Rationale: Expanded King's product portfolio and market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends varied based on product launches, acquisitions, and market competition prior to being acquired by Pfizer.
Future Projections: Future projections for King Pharmaceuticals as a standalone entity are non-existent, as it is now part of Pfizer.
Recent Initiatives: Recent initiatives are not applicable as the company no longer exists independently.
Summary
King Pharmaceuticals, once a significant player in the pain management and cardiovascular spaces, successfully carved a niche for itself before being acquired by Pfizer. The company's product portfolio and marketing prowess were its strengths, but reliance on opioids and patent expirations posed challenges. Although its independent existence ceased, it contributed to the broader pharmaceutical landscape and shareholder value when purchased. It remains important to study historical figures like KING to understand market dynamics.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (historical), Company Press Releases (historical), Market Research Reports (historical)
- Yahoo Finance
Disclaimers:
Data represents historical information prior to the Pfizer acquisition. Market share estimates are approximate and may vary based on source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About KING PHARMACEUTICALS INC
Exchange NYSE | Headquaters - | ||
IPO Launch date 1998-06-25 | CEO & Director Mr. Bradford Luke Ledbetter | ||
Sector Financial Services | Industry Insurance Brokers | Full time employees - | Website https://www.kestrelgroup.com |
Full time employees - | Website https://www.kestrelgroup.com | ||
Kestrel Group Ltd engages in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers. The company is based in Hamilton, Bermuda.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.